Phase 3 Readout

MNOV: Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to

Name: Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to
Start: 2028-04-01
End: 2028-04-01

April 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: April 1, 2028
Company: MEDICINOVA INC (MNOV)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to

April 1, 2028

MNOV overview →

Company: MEDICINOVA INC (MNOV)
Indication: Amyotrophic Lateral Sclerosis